ArticleClinical rheumatology2025
Impact of early treatment on the relapse-free survival and glucocorticoid dosing in giant cell arteritis: a retrospective cohort study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effect of early glucocorticoid treatment in new-onset giant cell arteritis (GCA) on relapse occurrence during glucocorticoid tapering, and on glucocorticoid dosages.
methodsThis retrospective cohort study included adults with GCA managed between 2017-2023 with at least three months of follow-up. Data collected included demographics, symptoms, treatment onset, glucocorticoid dosing, and disease relapses for up to 24 months after diagnosis. Early treatment was defined as initiation of glucocorticoids within 7 days of symptom onset. Disease relapses during the first glucocorticoid taper were defined as symptom recurrence or increased inflammatory markers attributed to GCA during or within three months of glucocorticoid tapering. Relapse free survival was estimated using Kaplan-Meier analysis. Glucocorticoid dosing was compared using the Mann-Whitney U Test.
resultsNinety patients (mean age 74.8 years, 70% female) with GCA met the inclusion criteria. Median time from symptom onset to glucocorticoid administration was 13 days, with 34 (37.8%) patients receiving treatment within one week. Overall, 47 (52.2%) experienced a relapse during their first glucocorticoid taper. Early treatment was associated with significantly reduced odds of having a relapse during the first glucocorticoid taper (OR = 0.214, 95%CI = 0.085-0.538; p = 0.001), and increased mean relapse-free survival (17 vs 11.6 months, p = 0.011). This effect persisted after adjusting for demographics, symptoms, inflammatory markers, biopsy results, glucocorticoid doses, and tocilizumab co-administration. Additionally, early treatment was associated with significantly lower median glucocorticoids doses at 3-, 6-, and 9-month intervals.
conclusionEarly initiation of glucocorticoids in patients with GCA is associated with increased relapse-free survival and reduced glucocorticoids dosages. Key Points • Glucocorticoid treatment within seven days of symptom onset reduced the risk of GCA relapse. • Early glucocorticoid treatment prolongs relapse-free survival in patients with GCA. • Initiating glucocorticoids early in GCA is associated with reduced glucocorticoid doses during the tapering period.
Indexed as
Identifiers
40616748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.